MYH11

Across TCGA pan-cancer cohorts, MYH11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYH11 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYH11 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYH11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where MYH11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.698	0.311	.005	35	view →
CCRCC	DFS	Tertile	IV	0.198	0.887	.024	12	view →
GBM	DFS	Median	All	0.487	0.264	.011	8	view →
HNSC	DFS	Median	II,III,IV	0.909	0.982	.006	6	view →
LUAD	DFS	Quartile	II,III,IV	0.652	0.936	.003	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYH11–PDAC (OS)

Open the PDAC breakdown →